Product
Supplier
Encyclopedia
Inquiry
Home > Active Pharmaceutical Ingredients > Other Chemical Drugs > Cagrilintide for Sale > Cagrilintide cas1415456-99-3 loss weight diabetes
Cagrilintide  cas1415456-99-3 loss weight diabetes buy - large image1
Cagrilintide  cas1415456-99-3 loss weight diabetes buy - image1
Cagrilintide  cas1415456-99-3 loss weight diabetes buy - image2
Cagrilintide  cas1415456-99-3 loss weight diabetes buy - image3
Cagrilintide  cas1415456-99-3 loss weight diabetes buy - image4
Cagrilintide  cas1415456-99-3 loss weight diabetes buy - image5

Cagrilintide cas1415456-99-3 loss weight diabetes

66 Inquiries

Unit Price:

$1/G FOB

Get Latest Price
CAS No.:

1415456-99-3

Grade:

Pharmaceutical Grade

Content:

99%

Port:

shanghai

Packaging:

1G/BAG

Sample Available:

Yes

Price valid (until):

2029-03-29

Company Type:
Manufactory
Location:
China
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A
Average Lead Time:
350 days
Qualification:
Main Products:

PEG,Semaglutide

  • Product Description

  • Seller Information

  • Inquiry History

  • Description

    Product Name:Cagrilintide
    CAS:1415456-99-3

    Cagrilintide is a peptide hormone, mainly used to treat diabetes. It can lower blood sugar and control blood sugar levels.
    Cagrilintide has the following properties: - Appearance: white to almost white powder - Use: mainly used to treat type 2 diabetes.


                                             ------------------- Company Profile ------------------

    VITALGEN PHARMA CO., LIMITED. is devoted to researching, manufacturing and marketing medical raw materials. The company has established a multi-functional R&D center in Shenzhen Zhongcheng Biomedical Industrial Park, which has a group of innovativedrugs and generic drugs technicians and 60 foreign trade professionals.


    VITALGEN PHARMA CO., LIMITED has built 500 square meters of pilot laboratories, equipped with two sets of 50L glass reactor, four sets of 100L double reactor, six sets of 50L rotary evaporator and matching heating and cooling equipment, to complete the 10kg Pilot complex experiments in complex compounds, a steady cooperation of the amplification plant, from 100kg to the tonnage of the enlarged production.


     medicine has been highly recognized by many well-known enterprises in the industry and has become their main supplier with high-quality products, honest and pragmatic attitude and good customer service. Tianyuan Medicine is dedicated to provide customers both at home and abroad with advanced technology and reasonable price , Quality products and professional technical services.

    Shop Cagrilintide  cas1415456-99-3 loss weight diabetes-Detailed Image 1

    Shop Cagrilintide  cas1415456-99-3 loss weight diabetes-Detailed Image 2

    Shop Cagrilintide  cas1415456-99-3 loss weight diabetes-Detailed Image 3

    ECHEMI Editorial Reference

    Cagrilintide is a long-acting amylin analog and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Cagrilintide is characterized by its peptide structure and amylin receptor activity. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.

    Basic Info
    Product Name:

    Cagrilintide

    Other Name:

    ‌Cagrilitide、Cagrilintide acetate、Caglitide、Kagliptin、Cargliptin、Cargilinitide

    CAS No.:

    1415456-99-3

    Molecular Formula:

    C194H312N54O59S2

    Molecular Weight:

    0

    EC Number:

    206-141-6

    Color/Form:

    White to off-white

    Categories:

    Other Chemical Drugs

    Research
    Class:

    Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)

    Status:

    Investigational — Phase 3 (REDEFINE program, CagriSema combination)

    Mechanism:

    A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity.

    Activity note:

    Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.

    Source:

    MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.

    Clinical Development:

    NCT05249895; NCT05249882

    References
    PubChem:

    PubChem

    Disclaimer:

    Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Manufactory

    Main Products:

    PEG,Semaglutide

    Location:

    1003 SHINGIND BLDG 42-46 TAI LIN PAI RD KWAI CHUNG HONGKONG

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A

    Average lead Time:

    350 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    51-100

    Year of Establishment:

    2018

     VITALGEN PHARMA CO., LIMITED is an international leading high-tech enterprise focusing on large-scale biosynthesis of polypeptide drugs. We provide all-round products and services from drug research, clinical development to access to market for global biotechnology and pharmaceutical enterprises.

    We have professional and experienced engineers and scientists, providing new polypeptide drug biosynthesis solutions, which help partners stay ahead of the polypeptide drug discovery, clinical development and market production.
    We have more than 5000 square meters of R&D center and 20000 square meters of intelligent manufacturing base, which can meet the needs of different customers and products, while meeting the GMP conditions for drug production

  • Inquiry History
    66 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Cagrilintide

    10 MG Sep 23, 2026
    United States

    Cagrilintide

    25 MG Aug 31, 2026
    United States

    Cagrlintide

    1 MT Jul 31, 2026
    United Kingdom

    cagrilintrude

    20 MG Jul 21, 2026
    United States

    Cagrilintide

    1 KG Jul 17, 2026
    United States

    Cagrilintide

    30 MG May 26, 2026
    United Kingdom

    CAGRILLINTED

    10  May 3, 2026
    Hongkong, China

    Cagrilintide

    100 MG Apr 22, 2026
    United Kingdom

    Cagrilintide

    1 KG Apr 14, 2026
    Ireland

    Cagrilintide

    10 PCS Apr 14, 2026
    United States

    Cargrilintide

    10 MG Mar 19, 2026
    United Kingdom

    cagrilintide

    10 MG Feb 18, 2026
    China

    CagriSema cagrilintide 2.5mg+Samaglutide2.5mg

    10 MG Jan 26, 2026
    South Korea

    Cagrilintide

    500 MG Jan 21, 2026
    Pakistan

    cagrilintide

    1 KG Dec 26, 2025
    United States

    Cagrilintide

    20 MG Dec 19, 2025
    United Kingdom

    Cagrilintide

    100 MG Dec 10, 2025
    Canada

    All peptides

    1001 MT Nov 12, 2025
    United States

    Cagrilintide

    10 MG Oct 13, 2024
    United States

    Cagrilintide

    1 MG Jun 3, 2024
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.